In September 2022, Patsy McDonald was awarded an NIH High End Instrument grant (S10), for a $1.25M state-of-the-art "High Throughput, High Content Screening and Imaging system" that will be housed in the Analytical Microscopy core. The Opera Phenix Plus arrived in late December and is scheduled to be installed in the Analytical Microscopy Core on Jan 23.
Instructors Nate Ward and Chang Jiang from the DeNicola lab attended the Society for Redox Biology and Medicine annual meeting in Orlando to present their work. Nate received a travel award to attend the meeting.
The DeNicola lab participated in Miles for Moffitt.
DeNicola Lab instructor Nate Ward and postdoc Sang Jun Yoon published collaborative work characterizing a novel yeast homocysteine synthase in JBC.
Ronak Kundalia from the Smalley lab was selected to present his work "Combination BRAF/MEK inhibition improves survival with leptomeningeal disease from melanoma" at the Society for Neuro-Oncology Annual Meeting in Tampa. The project is a collaboration with Dr. Peter Forsyth and Dr. Gerald Wallace.
DeNicola Lab postdoc Laura Torrente published collaborative work characterizing novel Cu(II) biosensors in PNAS.
Inna Smalley was awarded an R21 from the NCI.
Chang Jiang from the DeNicola lab was awarded a K99 grant from the NIH/NCI.
Inna Smalley was awarded the Donald A. Adam Melanoma and Skin Cancer Center of Excellence (MSCCoE) and Cutaneous Oncology Award.
Gina DeNicola, Nate Ward and Yumi Kim from the DeNicola lab attended the Keystone Tumor metabolism meeting. Gina chaired the Redox Biology session and presented on "Cysteine metabolism in Cancer" and Nate presented a poster. Nate was awarded the NK and Irene Cheung Family Scholar Award to attend the Keystone Meeting.
DeNicola Lab Research Instructor Nate Ward published collaborative work understanding the role of iron in MAPK inhibitor resistance in pancreatic cancer in Cancer Discovery.
Cheyenne Schneider from the DeNicola lab graduated from USF with a M.S. degree in Molecular Medicine Research.
Janine DeBlasi from the DeNicola lab attended the CSHL Models and Mechanisms of Cancer Conference and presented a poster on her work understanding the role of NRF2 in tumor initiation and progression.
Alpha-Particle Therapy Targeted to Metastatic Uveal Melanoma
A first-in-human clinical trial to test a new targeted alpha-particle therapy in patients with metastatic uveal melanoma was opened at Moffitt Cancer Center in July 2022. Development of this new peptide receptor radiotherapy (PRRT) began eight years ago in the Morse laboratory and a multidisciplinary team performed preclinical studies led by Dr. Morse (biological studies), Dr. Moros and Tichacek (medical physics), Dr. McLaughlin (peptide chemistry, now at West Virginia University), and Dr. Wadas (radiochemistry, now at University of Iowa). Pre-IND studies were performed in collaboration with Modulation Therapeutics Inc. The clinical team at Moffitt, pictured above, administered targeted alpha particle therapy to patients for the first time in August 2022 and are following tolerability, efficacy, pharmacokinetics and radiation dosimetry. They include from left, Rebecca Rogers (Nuclear Medicine tech), William Gibbons (Radiation Safety official), Ghassan El-Haddad, MD (Interventional Radiology and Nuclear Medicine), Ken Gage MD, PhD (Nuclear Medicine), Nikhil Khushalani MD (Chief, Medical Oncology), Christopher Tichacek PhD, (Medical Physicist in Radiation Oncology) and Mikalai Budzevich PhD, (manager of the SAIL core).
DeNicola Lab Postdoctoral Fellow Nathan Ward and Silva lab Applied Postdoctoral Fellow Praneeth Reddy Sudalagunta were awarded the Research Instructor designation.
DeNicola Lab Research Instructor Chang Jiang published her work using CRISPR screening to identify redox vulnerabilities for NRF2/KEAP1 mutant lung cancer cells in Redox Biology.
Inna Smalley was awarded a Young Investigator Award from the Melanoma Research Alliance.
Moffitt and the Metabolism and Physiology Department Mourn the Loss of Former Chair Dr. Robert Gillies
The global research community lost a great leader, scientist and collaborator. Dr. Robert Gillies' vision and work over the past 14 years made an indelible mark on Moffitt Cancer Center's success and helped pave the future. Throughout his career, he was an incredible mentor to students, postdoctoral fellows and faculty. Read more
Rafael Renatino Canevarolo, representing Praneeth Reddy Sudalagunta, made an oral presentation of the research titled "Functional Genomic Landscape in Multiple Myeloma Identifies Novel Therapeutic Strategies," at the 2022 Moffitt Scientific Symposium.
Rafael Renatino Canevarolo received an Oral Presentation Award in the area of Quantitative Science at the 2022 Moffitt Scientific Symposium.
Moffitt Cancer Center sponsors the "Cancer Metabolism Showcase and Workshops," a postdoc and student-focused event featuring 20 oral presentations, 85 posters, and career development workshops from members of the academia, industry, publishing and NIH community. This event was co-organized by Dr. Gina DeNicola. DeNicola lab science was represented by Nathan (oral presentation), Chang Jiang (poster presentation), and Laura Torrente (poster presentation).
Praneeth Reddy Sudalagunta presented his research titled "Functional Genomic Landscape of Multiple Myeloma Informed by TCC-Avatar Data Identifies Novel Therapeutic Strategies" at the 2022 ORIEN Scientific Retreat in St. Petersburg, Florida.
Rafael Renatino Canevarolo was invited to participate as a speaker at the First Workshop on Molecular Biology promoted by the Graduate Program on Biosciences and Biotechnology Applied to Pharmacy, from the São Paulo State University (Brazil). Title of the presentation: "Clinical Evolution of Multiple Myeloma and its Association with Dynamic Epigenetic Profiles."